Furthermore, fALS-ALS patients should be screened for SOD1, FUS, and TARDBP, which in our cohort explain 50% of fALS-ALS cases, reaching 76.6% with C9orf72 testing (Fig. 2). Here, C9orf72 is linked to amyotrophic lateral sclerosis.